通过天眼查大数据分析，苏州昊帆生物股份有限公司共对外投资了6家企业，参与招投标项目9次，知识 产权方面有商标信息25条，专利信息93条，此外企业还拥有行政许可14个。 来源：金融界 昊帆生物最新一期业绩显示，截至2025一季报，公司营业总收入1.35亿元、同比增长48.21%，归属净利 润3479.90万元，同比增长16.66%，扣非净利润2801.55万元，同比增长8.71%，流动比率28.624、速动比 率26.963、资产负债率3.40%。 天眼查商业履历信息显示，苏州昊帆生物股份有限公司，成立于2003年，位于苏州市，是一家以从事化 学原料和化学制品制造业为主的企业。企业注册资本10800万人民币，实缴资本10800万人民币。公司法 定代表人为朱勇。 金融界消息 截至2025年8月25日收盘，昊帆生物（301393）报收于59.92元，上涨3.35%，换手率 13.24%，成交量5.57万手，成交金额3.32亿元。 资金流向方面，今日主力资金净流出4545.66万元，占比成交额13.68%。其中，超大单净流出4665.64万 元、占成交额14.04%，大单净流入119.98万元、占成交额0.36%，中 ...

Core Insights - The total salary scale for CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary for CFOs in the biopharmaceutical sector is 1.0042 million yuan [1] - The age distribution shows that CFOs aged 40-50 constitute 54% of the market, while those over 50 account for 38% [1] Salary Distribution - The salary distribution among CFOs is as follows: below 500,000 yuan (13%), 500,000-1,000,000 yuan (46%), 1,000,000-2,000,000 yuan (33%), and above 2,000,000 yuan (8%) [1] - The top five highest-paid CFOs are from Kanghong Pharmaceutical, Junshi Biosciences-U, Shenzhou Cell, Tebao Biologics, and Aopumai, with salaries of 3 million, 2.0602 million, 1.4297 million, 1 million, and 1 million yuan respectively [1] Salary Changes - The largest salary decrease was observed for Xu Baohong from Junshi Biosciences-U, with a year-on-year decline of 24.66% [1] - The largest salary increase was for Liu Liwen from Zhixiang Jintai-U, with a year-on-year increase of 35.91% [1]

证券代码：301393 证券简称：昊帆生物 公告编号：2025-041 苏州昊帆生物股份有限公司 关于 2024 年限制性股票激励计划首次授予部分 第一个归属期归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1. 本次归属数量：21 万股，占目前公司总股本的 0.19%； 2. 本次归属人数：122 人； 3. 本次归属股票上市流通安排：本次归属的限制性股票无限售安排，股票 上市后即可流通，上市流通日为 2025 年 8 月 4 日。 4、激励对象：本激励计划授予的激励对象为公司公告本激励计划时在公司 任职的核心骨干及董事会认为需要激励的其他人员，具体分配如下： 苏州昊帆生物股份有限公司（以下简称"公司"或"昊帆生物"）于 2025 年 7 月 18 日召开第四届董事会第十一次会议和第四届监事会第九次会议，审议 通过了《关于 2024 年限制性股票激励计划首次授予部分第一个归属期符合归属 条件的议案》，截至本公告披露之日，公司已在中国证券登记结算有限责任公司 深圳分公司办理完成 2024 年限制性股票激励计划（以下简称 ...

Group 1 - The core viewpoint of the news is that Suzhou Haofan Biological Co., Ltd. (昊帆生物) has shown significant revenue growth in its latest quarterly report, indicating a positive financial performance despite a recent decline in stock price [1][3] - As of August 1, 2025, the company's stock closed at 59.05 yuan, down 4.28%, with a trading volume of 5.91 million shares and a transaction amount of 362 million yuan [1] - The company reported total revenue of 135 million yuan for the first quarter of 2025, representing a year-on-year growth of 48.21%, and a net profit attributable to shareholders of 34.79 million yuan, up 16.66% year-on-year [1] Group 2 - The company has a current liquidity ratio of 28.624 and a quick ratio of 26.963, indicating strong short-term financial health [1] - The debt-to-asset ratio stands at 3.40%, suggesting low leverage and financial risk [1] - Haofan Biological has made investments in 6 companies and participated in 9 bidding projects, showcasing its active engagement in business expansion [2]

Core Viewpoint - Haofan Bio (301393.SZ) is currently experiencing a decline in stock price, trading at 59.05 yuan with a drop of 4.28%, resulting in a total market capitalization of 6.377 billion yuan [1] Group 1: IPO Details - Haofan Bio was listed on the Shenzhen Stock Exchange's ChiNext board on July 12, 2023, with an initial public offering (IPO) of 27 million shares at a price of 67.68 yuan per share [1] - The total amount raised from the IPO was 1.82736 billion yuan, with a net amount of 1.6553887 billion yuan after deducting issuance costs [1] - The net amount raised exceeded the original plan by 510.3887 million yuan, which was initially set at 1.145 billion yuan [1] Group 2: Fund Utilization - The funds raised are intended for several projects, including the development and production of 100kg/year peptide and protein reagents, construction of a headquarters, and a project for producing 1,002 tons of peptide reagents and pharmaceutical intermediates [1] - Additional allocations include the establishment of a research platform for peptides and protein reagents and supplementing working capital [1] Group 3: Issuance Costs - The total issuance costs for the IPO amounted to 171.9713 million yuan, with underwriting and sponsorship fees accounting for 146.1888 million yuan [1]

Core Viewpoint - Suzhou Haofan Biological Co., Ltd. has approved the cancellation of 16,000 unvested restricted stocks due to three incentive recipients leaving the company for personal reasons, which will not materially affect the company's financial status or operational results [3][4]. Summary by Sections 1. Decision-Making Process and Disclosure - The company held meetings to review and approve the 2024 Restricted Stock Incentive Plan and its related proposals, which were passed by the Board of Directors and the Compensation and Assessment Committee [1][2]. 2. Verification by Supervisory Board - The Supervisory Board verified the list of incentive recipients and issued opinions on the related matters, confirming no objections were raised during the public notice period [2]. 3. Cancellation of Restricted Stocks - The cancellation of 16,000 restricted stocks was due to three individuals no longer qualifying as incentive recipients, as per the regulations outlined in the management measures and the incentive plan [3][4]. 4. Impact on the Company - The cancellation of these restricted stocks is not expected to have a significant impact on the company's financial condition or operational results, nor will it affect the stability of the core team or the implementation of the stock incentive plan [4]. 5. Opinions from Committees and Legal Advisors - The Compensation and Assessment Committee and legal advisors confirmed that the cancellation complies with relevant laws and regulations, and does not harm the interests of the company or its shareholders [5].

Core Points - The company has conducted a review of the first vesting list for the 2024 restricted stock incentive plan, confirming that the incentive objects meet the necessary qualifications as per relevant laws and regulations [1][2] - A total of 122 incentive objects have achieved the performance assessment requirements for the 2024 restricted stock incentive plan, with 3 individuals disqualified due to personal reasons [2] - The total number of restricted stocks to be vested for the eligible incentive objects is 210,000 shares, which complies with the legal and regulatory conditions [2] Summary by Sections - **Incentive Plan Review** - The board's remuneration and assessment committee has verified that the incentive objects do not fall under any disqualifying conditions as outlined in the relevant laws and regulations [1] - **Performance Assessment** - The individual performance results of the 122 incentive objects have met the assessment criteria, allowing them to qualify for the restricted stock vesting [2] - **Vesting Details** - The committee has approved the vesting of 210,000 shares of restricted stock to the eligible incentive objects, confirming that this action does not harm the interests of the company or its shareholders [2]

Group 1 - The core point of the announcement is the approval of the first vesting period of the 2024 restricted stock incentive plan, allowing 122 eligible participants to receive a total of 210,000 shares [1][2] - The supervisory board confirmed that the vesting conditions for the first part of the restricted stock incentive plan have been met, in accordance with relevant laws and regulations [1][2] - The voting results showed unanimous support from all three supervisors, with 100% in favor and no abstentions or oppositions [2][3] Group 2 - The supervisory board also approved the cancellation of certain previously granted but unvested restricted stocks, which complies with the relevant legal and regulatory requirements [2][3] - The decision to cancel the unvested stocks was deemed not to harm the interests of the company or its shareholders [2]

证券简称：昊帆生物 证券代码：301393 上海荣正企业咨询服务（集团）股份有限公司 关于 苏州昊帆生物股份有限公司 2024 年限制性股票激励计划 首次授予部分第一个归属期符合归属条件 及作废部分限制性股票相关事项 之 独立财务顾问报告 2025 年 7 月 | 一、释义 | 3 | | | | --- | --- | --- | --- | | 二、声明 | 4 | | | | 三、基本假设 | 5 | | | | 四、独立财务顾问意见 | 6 | | | | （一）已履行的决策程序和信息披露情况 6 | （二）本次实施的限制性股票股权激励计划与股东大会审议通过的限制性股 | | | | 票激励计划差异情况 7 | （三）董事会关于满足 | 年限制性股票激励计划首次授予部分第一个归属 | 2024 | | 期归属条件成就的说明 7 | （四）本次归属的具体情况 9 | | | | （五）本次作废处理限制性股票的原因和数量 9 | （六）结论性意见 10 | | | | 五、备查文件及咨询方式 | 11 | | | | （一）备查文件 11 | （二）咨询方式 11 | | | | 昊帆生物、本公司、 | ...

第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 苏州昊帆生物股份有限公司（以下简称"公司"）第四届董事会第十一次会 议于 2025 年 7 月 18 日在公司会议室以通讯方式召开，会议通知于 2025 年 7 月 15 日以专人送达及电话等方式发出。 证券代码：301393 证券简称：昊帆生物 公告编号：2025-037 苏州昊帆生物股份有限公司 本次会议由董事长朱勇先生主持，会议应出席董事 9 人，实际出席 9 人。公 司全体监事、高级管理人员列席本次会议。本次会议的召集、召开符合《中华人 民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 （二）审议并通过《关于作废部分已授予尚未归属的限制性股票的议案》 鉴于本次激励计划中有 3 名激励对象因个人原因离职，已不具备激励对象资 格，董事会同意根据 2024 年第一次临时股东大会的授权作废部分已授予但尚未 归属的限制性股票合计 1.6 万股。 表决结果：9名赞成，占全体董事人数的100%；0名弃权，0名反对。 公司董事会薪酬与考核委员会对 ...